A Phase 1 interventional study of Selpercatinib and Omeprazole in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to assess the effect of food on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it after a high-fat meal, and the effect of a change in gastric pH after multiple doses of omeprazole on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it when administered under fasted and fed conditions in healthy participants. The study will also evaluate the safety and tolerability of selpercatinib in healthy participants. The study will last up to 33 days excluding the screening period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received: * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fasted state. * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fed state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 3 in fasted state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 4 in fed state. Periods 1 and 2, 2 and 3 were separated by a 7-day washout period. There was no washout between Periods 3 and 4.
Drug: Selpercatinib · Drug: Omeprazole
Participants received: * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fasted state. * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fed state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 3 in fed state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 4 in fasted state. Periods 1 and 2, 2 and 3 were separated by a 7-day washout period. There was no washout between Periods 3 and 4.
Drug: Selpercatinib · Drug: Omeprazole
Participants received: * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fed state. * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fasted state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 3 in fasted state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 4 in fed state. Periods 1 and 2, 2 and 3 were separated by a 7-day washout period. There was no washout between Periods 3 and 4.
Drug: Selpercatinib · Drug: Omeprazole
Participants received: * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fed state. * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fasted state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 3 in fed state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 4 in fasted state. Periods 1 and 2, 2 and 3 were separated by a 7-day washout period. There was no washout between Periods 3 and 4.
Drug: Selpercatinib · Drug: Omeprazole
Administered orally
Also known as: LY3527723, LOXO-292
Administered orally
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
PK: AUC0-t of Selpercatinib was reported.
Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib
PK: AUC0-inf of Selpercatinib was reported.
Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib
PK: AUC%extrap of Selpercatinib was reported.
Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
PK: Maximum Observed Concentration (Cmax) of Selpercatinib
PK: Cmax of Selpercatinib was reported.
Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
PK: Time to Reach Cmax (Tmax) of Selpercatinib
PK: Tmax of Selpercatinib was reported.
Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib
PK: Kel of Selpercatinib was reported.
Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib
PK: CL/F of Selpercatinib was reported.
Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib
PK: t½ of Selpercatinib was reported.
Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
A total of 20 participants were enrolled in this study. Participants were randomly assigned to 1 of 4 treatment sequences (ABCD, ABDC, BACD, and BADC). Treatment A was a single oral dose of 160 milligrams (mg) selpercatinib under fasting condition, Treatment B was a single oral dose of 160 mg selpercatinib under fed condition, (contd.)
| Milestone | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC |
|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 |
| Received at least 1 dose of study drug | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC |
|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 |
| Received at least 1 dose of study drug | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC |
|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 |
| Received at least 1 dose of study drug | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC |
|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 |
| Received at least 1 dose of study drug | 5 | 5 | 5 | 4 |
| Completed | 5 | 5 | 5 | 4 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
PK: AUC0-t of Selpercatinib was reported.
| nanogram*hour per milliliter (ng*h/mL) | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib | 26160 ± 38.9 | 28400 ± 20.4 | 7973 ± 161.9 | 26570 ± 14.1 |
PK: AUC0-inf of Selpercatinib was reported.
| ng*h/mL | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib | 26280 ± 38.9 | 28530 ± 20.4 | 8256 ± 143.3 | 26770 ± 13.8 |
PK: AUC%extrap of Selpercatinib was reported.
| percentage of AUC0-inf extrapolated | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib | 0.4468 ± 0.14909 | 0.4541 ± 0.22000 | 3.065 ± 7.5841 | 0.7158 ± 0.46382 |
PK: Cmax of Selpercatinib was reported.
| nanograms per milliliter (ng/mL) | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Selpercatinib | 2024 ± 60.4 | 1745 ± 20.9 | 251.5 ± 263.9 | 1023 ± 24.7 |
PK: Tmax of Selpercatinib was reported.
| hours (h) | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| PK: Time to Reach Cmax (Tmax) of Selpercatinib | 1.502 (1.00 to 24.00) | 3.997 (2.01 to 6.00) | 2.501 (1.50 to 23.97) | 6.011 (3.00 to 23.93) |
PK: Kel of Selpercatinib was reported.
| 1/hour | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib | 0.02445 ± 0.0058755 | 0.02282 ± 0.0047476 | 0.02207 ± 0.0095909 | 0.02214 ± 0.0077557 |
PK: CL/F of Selpercatinib was reported.
| Liters/hour | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib | 6.585 ± 3.2392 | 5.717 ± 1.1560 | 50.45 ± 135.82 | 6.031 ± 0.81650 |
PK: t½ of Selpercatinib was reported.
| h | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib | 29.801 ± 6.6155 | 31.641 ± 6.5273 | 37.288 ± 16.0167 | 35.841 ± 14.7170 |
Collected over Baseline to End of Follow-up (Up To 39 Days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: 160 mg Selpercatinib (Fasted) | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Treatment B: 160 mg Selpercatinib (Fed) | 0/20 (0%) | 0/20 (0%) | 6/20 (30%) |
| Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | 0/19 (0%) | 0/19 (0%) | 7/19 (36.8%) |
| Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) | 0/20 (0%) | 0/20 (0%) | 8/20 (40%) |
| Event | Treatment A: 160 mg Selpercatinib (Fasted) | Treatment B: 160 mg Selpercatinib (Fed) | Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted) | Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/20 | 0/20 | 3/19 | 2/20 |
| Abdominal discomfortGastrointestinal disorders | 0/20 | 0/20 | 0/19 | 2/20 |
| DyspepsiaGastrointestinal disorders | 0/20 | 2/20 | 0/19 | 1/20 |
| FlatulenceGastrointestinal disorders | 0/20 | 0/20 | 0/19 | 2/20 |
| Abdominal pain lowerGastrointestinal disorders | 0/20 | 0/20 | 1/19 | 0/20 |
| Abdominal pain upperGastrointestinal disorders | 0/20 | 0/20 | 1/19 | 0/20 |
| Alanine aminotransferase increasedInvestigations | 0/20 | 0/20 | 1/19 | 1/20 |
| Blood creatine phosphokinase increasedInvestigations | 0/20 | 0/20 | 1/19 | 0/20 |
| Weight decreasedInvestigations | 0/20 | 0/20 | 1/19 | 1/20 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 1/20 | 0/20 | 1/19 | 1/20 |
All enrolled participants.
| Age, Continuous(years) | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC | Total |
|---|---|---|---|---|---|
| Mean | 45.0 ± 6.82 | 38.2 ± 6.50 | 41.8 ± 10.35 | 38.4 ± 7.44 | 40.9 ± 7.82 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC | Total |
|---|---|---|---|---|---|
| Female | 3 | 2 | 2 | 3 | 10 |
| Male | 2 | 3 | 3 | 2 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 5 | 5 | 19 |
| Not Hispanic or Latino | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 5 | 4 | 5 | 5 | 19 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Treatment Sequence 1: ABCD | Treatment Sequence 2: ABDC | Treatment Sequence 3: BACD | Treatment Sequence 3: BADC | Total |
|---|---|---|---|---|---|
| United States | 5 | 5 | 5 | 5 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2018 to primary completion in Sep 2018, 3 months.
Results were first posted in Sep 2025, 7 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib